GBI Research found that on average biobetter launches generate more revenues than their corresponding originator therapies. In some scenarios this extended to, the launch of a biobetter therapy substituting the sales from an existing originator product or biobetter therapy.
- Data and analysis on the impact of biobetter therapeutics on the major top selling biologics erythropoietin's, granulocyte-colony stimulating factors (G-CSF), interferon-?, interferon-beta, insulin and insulin analogs, human growth hormone and monoclonal and mAbs.- Pipeline analysis of biobetter therapies in major protein classes erythropoietin's, G-CSF, interferon-?, interferon-beta, insulin and insulin analogs, mAbs and TNF-?.- Key drivers and restraints that have had a significant impact on the market.- The competitive landscape of the global biobetter therapeutics market, including companies such as Celgene, Amgen, Bristol-Myers Squibb, Amylin and Dainippon Sumitomo Pharma.- Key M&A activities and licensing and co-development agreements that took place from 2010-2012 in the global Biobetters market.
Reasons to buy
- Align your product portfolio to the markets with high growth potential.- Develop business strategies by understanding the trends shaping and driving technological advancements in the field of biobetter therapies.- Identify key molecules in development being used for biobetter therapies. - Reinforce R&D pipelines by identifying common drug class biobetters in the pipeline for top selling protein classes.- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.Table of Contents
1 Table of Contents1 Table of Contents 61.1 List of Tables 81.2 List of Figures 82 Introduction 93 Global Market Overview 113.1 Biobetter Therapies Already on the Market 113.1.1 Erythropoietins 123.1.2 Granulocyte-colony Stimulating Factors 143.1.3 Interferon-?, Interferon-
Copyright©2012 PR Newswire.
All rights reserved